Hikal announces the successful development of Favipiravir Active Pharmaceutical ingredient (API) and its intermediates

May 15, 2020

India

healthysoch

New Delhi, May 15, 2020 :

Hikal Limited, a leading manufacturer and supplier of API’s and intermediates globally  announced the successful development of Favipiravir Active Pharmaceutical ingredient (API) and its intermediates. Favipiravir is a generic version of Avigan of Fujifilm Toyama Chemical Co. Ltd., Japan, a subsidiary of Fujifilm Corporation. Favipiravir has demonstrated activity against influenza viruses and has been approved in Japan for the treatment of novel influenza virus infections. It is in various stages of clinical trials in many countries as an experimental treatment of COVID-19.

The company is in discussion with potential partners to supply the API and its intermediates.

Hikal has developed this API in a record amount of time to make the product available for treatment of COVID-19. This demonstrates Hikal’s commitment to support in the fight against COVID-19 virus and to provide high quality medicines to its customers globally.

healthysoch

Stay informed with the latest news from HealthySoch. Sign up today for exclusive insights and updates!

We promise we never spam!

Leave a Reply

Your email address will not be published.

Columnists

HealthySoch

Don't Miss

Substantial investment needed to avert mental health crisis

India healthysoch Geneva, New Delhi, May 15, 2020 : The

Fortis brings together Cancer Survivors, shares stories of hope & joy!  

India healthysoch New Delhi, February 04, 2021 : On the